Oramed Pharmaceuticals Inc. (ORMP.OB) Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
5/17/2013 9:36:51 AM
More...
|
Clinical Results for Oramed Pharmaceuticals Inc. (ORMP.OB)'s Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
5/1/2013 10:11:00 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4/30/2013 7:14:18 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) CEO to be Panelist at Biotechnology Industry Organization (BIO) International Convention Breakout Session on Israel Becoming Biotech Leader
4/22/2013 7:38:31 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
4/18/2013 9:40:01 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
.
4/18/2013 6:43:40 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Appoints New Chief Operating Officer and VP of Business Development
4/16/2013 7:41:02 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Submits New IND Application for Oral Insulin Trial in the US
4/11/2013 9:42:51 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Granted Japanese Patent for Its Core Technology in Oral Delivery of Proteins
4/3/2013 11:18:25 AM
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Selected to Present at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL, June 21-25, 2013
3/22/2013 9:17:40 AM
More...
|
|